Before weighting, patients with prescriptions for GLP-1 receptor agonists were more likely to be female and to have obesity, a longer duration of diabetes, a higher level of haemoglobin A 1c , more microvascular complications, and a history of depression compared with those treated with SGLT-2 inhibitors
To view or add a comment, sign in More Relevant Posts The FDA on Thursday handed Novo Nordisk a fast-tracked clearance for a high-dose (HD) version of its blockbuster obesity drug Wegovy (semaglutide)
For the medicine, only side effects are described that have so far only occurred in exceptional cases
Everything is designed so you can enjoy yourself without any worries
Depressions multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways
Clinical appropriateness is determined on an individual basis